Super Investors Be Like
RWAY

Runway Growth Finance — Financial Results

AI Overview

Investment Income and Profitability Are Declining as the Portfolio Shrinks

Metric202320242025
Total investment income$164.2M$144.6M$137.3M
Net investment income (NII)$78.3M$63.8M$56.9M
NII per share$1.93$1.64$1.55

Net investment income (the core earnings measure for a lender like this — interest and fees collected minus operating costs) has fallen 27% over two years. Two forces are driving this: the overall loan portfolio shrank from roughly $1.1 billion to $927 million, and falling interest rates reduced what the company earns on its floating-rate loans. The portfolio yield on debt investments dropped from 15.8% in 2023 to 14.6% in 2025.

Dividends Paid Have Been Cut Meaningfully

YearTotal Dividends PaidPer Share (Implied)
2023$73.3M
2024$69.9M
2025$51.4M

The company paid out $51.4 million in distributions in 2025, down 26% from 2023. This follows the decline in net investment income — the company is paying out what it earns, which is common for a BDC (Business Development Company), a type of regulated fund that must distribute most of its income. The most recently declared quarterly dividend of $0.33 per share gives a useful forward reference for income-focused investors.

Portfolio Credit Quality Has Deteriorated Slightly

RatingDec 2024 Fair Value%Dec 2025 Fair Value%
Rating 1 (Best)$27.2M2.53%$6.6M0.71%
Rating 4 (Near Default)$34.1M3.17%$74.0M7.98%

The share of loans rated 4 — meaning the borrower is materially behind plan and a payment default is possible without corrective action — jumped from 3.2% to 8.0% of the debt portfolio. This is worth watching. On the positive side, non-accrual loans (loans where the company has stopped recording interest because repayment is in doubt) actually improved, falling from 0.52% to 0.25% of the portfolio.

A Merger with SWK Holdings Is Pending

The company signed a Merger Agreement on October 9, 2025, under which SWK Holdings Corporation would merge into Runway Growth Finance. SWK is another specialty finance lender, focused on life science royalty monetization. The filing flags standard merger risks — regulatory approval, shareholder votes, potential deal disruption, and integration challenges. No financial terms of the merger are disclosed in this section, but the outcome would meaningfully change the combined company's size and strategy.

The Balance Sheet Was Actively Refinanced

Shortly after year-end, the company repaid its April 2026 Notes and redeemed portions of two 2027 note series, then raised $103.25 million through a new 7.25% fixed-rate unsecured bond maturing in 2031. This extends the debt maturity profile (the schedule of when borrowed money comes due), reducing near-term repayment pressure. The asset coverage ratio — a regulatory measure of how much asset cushion sits above the company's debts, required to stay above 150% — improved from 192% to 211%, giving the company more financial flexibility.